Kevin Dunleavy

Kevin Dunleavy and Eric Saganowski, experts from Fierce Pharma, dive into the whirlwind of 2025 FDA drug approvals. They analyze the surprising surge in approvals despite agency turmoil and layoffs. The duo reveals that European firms outperformed US companies, and 57% of new drugs were for rare diseases. Insightful discussions cover the declining trend in blockbuster drugs and the implications of fewer advisory committee meetings. With a focus on oncology and the complexities of drug development, this conversation sheds light on the future of biopharma.